Safety qualms in MyoKardia mid-stage study cause investors to pause

Ahead of the pivotal data readout of MyoKardia’s lead drug, mavacamten, in patients with obstructive hypertrophic cardiomyopathy (HCM), investors took issue with the drug’s safety profile in a separate Phase II non-obstructive HCM study.